Cargando…

Genes versus Environment: cytoplasmic BAP1 determines the toxic response to environmental stressors in mesothelioma

Detalles Bibliográficos
Autor principal:	Amelio, Ivano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	News and Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520942/ https://www.ncbi.nlm.nih.gov/pubmed/28661472 http://dx.doi.org/10.1038/cddis.2017.293

Ejemplares similares

Exploiting tumour addiction with a serine and glycine-free diet
por: Amelio, Ivano, et al.
Publicado: (2017)

BAP1 in cancer: epigenetic stability and genome integrity
por: Caporali, Sabrina, et al.
Publicado: (2022)

Structural and Biophysical Characterization of the Cytoplasmic Domains of Human BAP29 and BAP31
por: Quistgaard, Esben M., et al.
Publicado: (2013)

BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
por: Guazzelli, Alice, et al.
Publicado: (2019)

Deconvoluting gene and environment interactions to develop an “epigenetic score meter” of disease
por: Butera, Alessio, et al.
Publicado: (2023)

Germline BAP1 mutations predispose to malignant mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2011)

A case for combined environmental stressor studies
por: Tipton, Michael
Publicado: (2012)

CRISPR: a new method for genetic engineering – A prokaryotic immune component may potentially open a new era of gene silencing
por: Amelio, I, et al.
Publicado: (2015)

Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
por: Pulford, Emily, et al.
Publicado: (2017)

Non-Genomic AhR-Signaling Modulates the Immune Response in Endotoxin-Activated Macrophages After Activation by the Environmental Stressor BaP
por: Großkopf, Henning, et al.
Publicado: (2021)

Novel function of cytoplasmic p53 at the interface between mitochondria and the endoplasmic reticulum
por: Kroemer, G, et al.
Publicado: (2015)

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
por: Ladanyi, Marc, et al.
Publicado: (2019)

Helicobacter pylori VacA toxin causes cell death by inducing accumulation of cytoplasmic connexin 43
por: Yahiro, K, et al.
Publicado: (2015)

BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
por: Carbone, Michele, et al.
Publicado: (2012)

BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma
por: Alakus, Hakan, et al.
Publicado: (2015)

The Rarest of the Rare: A Case of BAP1-Mutated Primary Peritoneal Mesothelioma
por: Gupta, Aanchal, et al.
Publicado: (2021)

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
por: Pandey, Gaurav Kumar, et al.
Publicado: (2023)

Bispecific antibodies come to the aid of cancer immunotherapy
por: Amelio, Ivano, et al.
Publicado: (2021)

Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma
por: Kalra, Neetu, et al.
Publicado: (2015)

Bilateral Pleural Mesothelioma In Situ and Peritoneal Mesothelioma In Situ Associated With BAP1 Germline Mutation: A Case Report
por: MacLean, Alyssa, et al.
Publicado: (2022)

Where There Is Asbestos, There Is Mesothelioma: Filling in the Data Blanks
por: Haynes, Rebecca Clay
Publicado: (2011)

p53-guided response to nucleostemin loss in normal versus cancer cells
por: Tsai, R Y L
Publicado: (2015)

Understanding drug-cytokine synergistic toxicity
por: Wolenski, F S, et al.
Publicado: (2015)

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
por: Shrestha, Raunak, et al.
Publicado: (2019)

BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma
por: Ishii, Yuki, et al.
Publicado: (2021)

Case report: Mesothelioma and BAP1 tumor predisposition syndrome: Implications for public health
por: Vimercati, Luigi, et al.
Publicado: (2022)

Cytoplasmic enzymes cast NETs
por: Leslie, Mitch
Publicado: (2010)

Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic Response
por: Osmanbeyoglu, Hatice Ulku, et al.
Publicado: (2022)

A mechanism for the tissue specificity in BAP1 cancer syndrome
por: Machida, Yuichi J.
Publicado: (2019)

To BaP or not to BaP? That is the question.
por: Goldstein, L S
Publicado: (2001)

Cutaneous responses to environmental stressors
por: Valacchi, Giuseppe, et al.
Publicado: (2012)

Minor spliceosome, major surprise: it's cytoplasmic
por: Robinson, Richard
Publicado: (2007)

The cytoplasm gets some new threads
por: Short, Ben
Publicado: (2010)

Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members
por: Kittaneh, Muaiad, et al.
Publicado: (2018)

A case of slowly progressive malignant pericardial mesothelioma suggesting the involvement of BAP1 loss
por: Fukasawa, Naoto, et al.
Publicado: (2022)

Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma
por: Zuccatosta, Lina, et al.
Publicado: (2023)

Commentary: Case report: Mesothelioma and BAP1 tumor predisposition syndrome: implications for public health
por: Sassorossi, Carolina, et al.
Publicado: (2023)

Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma
por: Carbone, Michele, et al.
Publicado: (2023)

CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma
por: Karnan, Sivasundaram, et al.
Publicado: (2023)

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene
por: Ghafoor, Azam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4arqghe6uc75e4d1h74d9aokn1